Zylox-tonbridge Medical Technology Co., Ltd. Class H · HKEX:2190
Zylox-tonbridge Medical Technology Co., Ltd. Class H — FY2021 Earnings Presentation
32 slides from Zylox-tonbridge Medical Technology Co., Ltd. Class H's earnings presentation, April 2022
Slide 1: 2021 Annual Results Presentation
2021 Annual Results Presentation APRIL 2022
Slide 2: Disclaimer
Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase
Slide 3: Agenda
Agenda 1 Business Highlights 2 Product and Business Updates 3 Financial Updates 4 Summary 3
Slide 4: Business Highlights
SECTION 1 Business Highlights
Slide 5: Efficient Product R&D Lays a Solid Foundation for Continuous Growth
Efficient Product R&D Lays a Solid Foundation for Continuous Growth Achieve the Goal of Approved Products in 2021 R&D Pipelines Progressed Successfully Approval Time in 2021 Products in China(1) Q1 Q2 Q3 Q4 Intracranial Balloon 1 Catheter (Rx) Peripheral Venous 2 Distal Access Catheter Flow Diverter
Slide 6: Commercialization of High-quality Products Triggered Rapid Revenue Growth
Commercialization of High-quality Products Triggered Rapid Revenue Growth Rapid Revenue Growth in 2021 Sufficient Funds and Efficient Operations (RMB in thousands) (RMB in thousands) GPM： 24.2% 58.9% 74.1% 200,000 3,500,000 2,918,359 177,912 3,000,000 160,000 2,500,000 65,641 2,000,000 120,000 544%
Slide 7: Product and Business Updates
SECTION 2 Product and Business Updates
Slide 8: Robust R&D Pipelines Bolster the Long-term Growth
Robust R&D Pipelines Bolster the Long-term Growth 41 new products expected to 16 23 2 be approved domestically in the Neurovascular Peripheral-vascular Vascular Closure upcoming 4 years Interventional Products Interventional Products Devices Category As of Dec 31, 2021 2022 2023 2024 2025 14 approve
Slide 9: Products Update - Neurovascular Interventional Portfolio
Products Update - Neurovascular Interventional Portfolio Intracranial Intracranial Intracranial Carotid Artery Diseases Hemorrhagic Ischemic Stroke Stenosis Stenosis Stroke • Thrombite® CRD / • Neurovascular • Intracranial Balloon • Carotid RX Balloon Approved by NMPA in Embolization Coils / Cathete
Slide 10: Neurovascular - Rapid Revenue Growth
Neurovascular - Rapid Revenue Growth Revenue of Neurovascular Products 10 Products Approved in China and CE (RMB in thousands) % of Revenue: - 72.2% 63.1% 120,000 112,271 Clot Retriever 100,000 Device 80,000 463% Intracranial 60,000 Balloon Catheter(Rx) 40,000 19,940 20,000 Intracranial 0 Support 0
Slide 11: Neurovascular - Products Expected to be Approved in 2022
Neurovascular - Products Expected to be Approved in 2022 Aspiration Neurovascular Carotid RX PTA Balloon Catheter Guidewire Catheter (1) Effects: Effects: Effects: • Expected to be used for • Expected to be used in • Intended for percutaneous revascularization in patients with neurovascular and peri
Slide 12: Neurovascular - Products Expected to be Approved in 2023
Neurovascular - Products Expected to be Approved in 2023 Second Generation Second Generation Clot Retriever Device Neurovascular Embolic Protection System Embolization Coils Effects: Effects: Effects: • Expected to be used for the • Dense embolization of • Intended for containment and treatment of r
Slide 13: Neurovascular - Key Hemorrhagic Stroke Products
Neurovascular - Key Hemorrhagic Stroke Products Flow Diverter Simultaneous advancement of clinical trials for 2 indications Small unruptured aneurysms (OPC) completed enrollment in November 2021 Deformable Proximal Large unruptured aneurysm RCT, more than half of Self-expanding Radiographic which ha
Slide 14: Products Update - Peripheral-vascular Interventional Portfolio
Products Update - Peripheral-vascular Interventional Portfolio Hemodialysis Diseases Arterial Venous Access • UItraFree® Drug Coated PTA • Snare Retrieval Kit for IVC Filter / • High Pressure PTA Balloon Balloon Catheter/ Launched Launched Catheter / Launched • Second Generation UItraFree® • Endovas
Slide 15: Peripheral-vascular - Rapid Revenue Growth
Peripheral-vascular - Rapid Revenue Growth Revenue of Peripheral-vascular Products 5 Products Approved in China and CE Respectively (RMB in thousands) % of Revenue: 100% 27.8% 36.9% 70,000 65,641 60,000 50,000 40,000 753% Drug Coated PTA High Pressure PTA Balloon Catheter Balloon Catheter 30,000 20,
Slide 16: Peripheral-vascular – Products Expected To be Approved in 22
Peripheral-vascular – Products Expected To be Approved in 2022 Arterial Venous Hemodialysis Access Endovenous Radiofrequency Ablation (RFA) Catheter Efficient treatment of the great saphenous vein with varicose veins using radiofrequency thermal closure technology UltraFree® Drug Coated PTA Balloon
Slide 17: Peripheral-vascular - Product Updates
Peripheral-vascular - Product Updates Intravascular Lithotripsy (IVL) System Product Structure Product Features Generator ▪ Circuit design with independent IP rights ▪ Submit nearly 10 invention patent applications Connector Intelligent Energy Control System ▪ High lithotripsy effectiveness, providi
Slide 18: Peripheral-vascular - Full Suite Solutions for Venous Diseases
Peripheral-vascular - Full Suite Solutions for Venous Diseases Pulmonary Embolism Product Line • Pulmonary Embolism Mechanical Thrombectomy Device Hepatic Portal Vein Stent Graft (acute pulmonary embolism) • TIPS Stent Graft System • Infusion Catheter (acute pulmonary embolism) Vena Cava Filter Prod
Slide 19: Peripheral-vascular - Product Updates
Peripheral-vascular - Product Updates Mechanical Thrombectomy Device Product Structure Product Features Utilize a purely mechanical thrombectomy method for removal of emboli and thrombi from pulmonary vessels by large bore aspiration and mechanical thrombectomy without thrombolysis Combines the adva
Slide 20: Product Updates - Overseas Portfolio
Product Updates - Overseas Portfolio Phase Expected Commercial Registration & Launch Preclinical Clinical Trials Product Approval Year UItraFree® Drug Coated PTA Balloon In 2021, overseas revenue Catheter Exempted from clinical CE Launched trial requirement was RMB3.46MM, UItraFree® Drug Coated PTA
Slide 21: Financial Updates
SECTION 3 Oe UE fel lf ti ™ 7 Financial Updates ZYLOX-TONBRIDGE
Slide 22: Rapid Growth Driven by Successful R&D and Commercialization
Rapid Growth Driven by Successful R&D and Commercialization Rapid Revenue Growth in 2021 GPM Improves with Sales Optimization (RMB in thousands) (RMB in thousands) GPM： 24.2% 58.9% 74.1% 200,000 200,000 180,000 160,000 160,000 65,641 140,000 131,881 120,000 120,000 544% 100,000 710% 80,000 80,000 11
Slide 23: Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years Adjusted Net Loss 2021 Cash Status (RMB in thousands) (RMB in thousands) 2019 2020 2021 3,500,000 0 (20,000) 3,000,000 2,918,359 2,809,823 (59,046) (40,000) (77,357) (100,745) 2,500,000 (60,000) (7,601) 2,000,000 (8
Slide 24: Increasing Operating Expenses Level in Line with Development
Increasing Operating Expenses Level in Line with Development Selling and Distribution Expenses R&D Expenses Administrative Expenses (RMB in thousands) (RMB in thousands) (RMB in thousands) % of Revenue(1) 137% 59% 45% 1,066% 237% 72% 203% 69% 32% 180,000 168,100 160,000 140,000 120,000 100,599 100,0
Slide 25: Accounts Receivable / Accounts Payable Turnover
Accounts Receivable / Accounts Payable Turnover Accounts Receivable Turnover Accounts Payable Turnover (Turnover Days) (Turnover Days) 300 80 270 70 68 242 240 60 210 50 180 150 40 120 107 30 90 73 20 60 10 7 30 NM (1) - - 2019 2020 2021 2019 2020 2021 Notes: 1. The calculation result of the average
Slide 26: Summary
SECTION 4 iui “7 Summary ZYLOX- a
Slide 27: Summary
Summary 1 The Most Comprehensive Product Portfolio in China - Provide full suite solutions for doctors and patients - Diversified product portfolio to reduce product revenue concentration - Attract high-quality dealers and enhance competitive advantage 2 Strong In-house R&D Capabilities - Dedicated
Slide 28: Appendix
Appendix Please refer to the 2021 Annual Report for further information Click to download the 2021 Annual Report
Slide 29: Consolidated Statements of Profit or Loss
Consolidated Statements of Profit or Loss Year ended December 31, 2021 Year ended December 31, 2021 RMB’000 2021 2020 Revenue 177,912 27,631 Cost of sales (46,031) (11,344) Gross Profit 131,881 16,287 Selling and distribution expenses (95,269) (20,453) Administrative expenses (100,599) (30,992) Rese
Slide 30: Consolidated Balance Sheet
Consolidated Balance Sheet Year ended December 31, 2021 As at RMB’000 December 31, 2021 December 31, 2020 Non-current assets Property, plant and equipment 178,270 105,224 Right-of-use assets 34,115 16,950 Intangible assets 4,889 7,556 Prepayments 6,804 4,099 Total non-current assets 224,078 133,829
Slide 31: Product Portfolio for Neurovascular Interventional Devices in China Market
Product Portfolio for Neurovascular Interventional Devices in China Market Stage Expected Registrational Commercial Product Design Type Testing Clinical & Approval Launch Year Thrombite® Clot Retriever Device Launched (Thrombite® CRD) Exempted from 2023 Clot Retriever Device ll clinical trial requir
Slide 32: Product Portfolio for Peripheral Vascular Interventional Devices and Vascular Closure Devices in China Market
Product Portfolio for Peripheral Vascular Interventional Devices and Vascular Closure Devices in China Market Stage Expected Registrational Commercial Product Design Type Testing Clinical & Approval Launch Year UltraFree® Drug Coated PTA Launched Balloon Catheter (UltraFree® DCB) Second Generation U
Zylox-Tonbridge Medical Technology — FY2021 Earnings Presentation on 6ix